Position in SCYX
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$32,259
+$11,155 QoQ
Shares Held
4,398
+5.4% QoQ
Ownership
0.044%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in SCYX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026RAYMOND JAMES FINANCIAL INC holds $625,710,198 across 33 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
1,741,371 | $125,134,918 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
580,170 | $97,781,849 | |
| 3 | HLN |
Haleon plc
|
7,278,875 | $67,911,902 | |
| 4 | ELAN |
Elanco Animal Health Inc
|
2,383,479 | $58,657,416 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
1,692,660 | $57,347,317 | |
| 6 | UTHR |
UNITED THERAPEUTICS Corp
|
55,173 | $29,894,385 | |
| 7 | VTRS |
Viatris Inc
|
1,668,730 | $26,499,430 | |
| 8 | LNTH |
Lantheus Holdings, Inc.
|
234,788 | $26,047,378 |
All Filings in SCYX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $32,259 | 35,180 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $21,104 | 33,395 | Shares | Defined | 2026-02-18 | |
| 2025-09-30 | $16,619 | 21,584 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $14,569 | 21,584 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $20,547 | 21,584 | Shares | Defined | 2025-05-13 | |
| No filing history on record for this holder in this stock. | ||||||